(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 35.3% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Geron's revenue in 2026 is $196,115,000.On average, 8 Wall Street analysts forecast GERN's revenue for 2026 to be $152,951,430,621, with the lowest GERN revenue forecast at $144,579,581,910, and the highest GERN revenue forecast at $161,823,665,692. On average, 8 Wall Street analysts forecast GERN's revenue for 2027 to be $217,988,826,965, with the lowest GERN revenue forecast at $180,524,002,084, and the highest GERN revenue forecast at $280,254,852,702.
In 2028, GERN is forecast to generate $318,130,251,007 in revenue, with the lowest revenue forecast at $214,319,326,994 and the highest revenue forecast at $506,455,148,134.